| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV.MED.55.091902.104344 |
| P698 | PubMed publication ID | 14746526 |
| P2093 | author name string | John W Shiver | |
| Emilio A Emini | |||
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 355-372 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Annual Review of Medicine | Q567363 |
| P1476 | title | Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors | |
| P478 | volume | 55 |
| Q42998134 | A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees |
| Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
| Q37647461 | A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. |
| Q42690486 | A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque |
| Q27472927 | A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques |
| Q45228579 | A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines |
| Q45879506 | A realistic chance for gene therapy in the near future |
| Q40344955 | A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults |
| Q40179544 | A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells |
| Q36024470 | A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge |
| Q45868889 | Activation of CFTR-specific T Cells in cystic fibrosis mice following gene transfer. |
| Q36979919 | Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells |
| Q33565630 | Adenoviral vector immunity: its implications and circumvention strategies |
| Q35990696 | Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. |
| Q51891172 | Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. |
| Q38308865 | Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery |
| Q40319132 | Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions |
| Q34938294 | Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation |
| Q37446484 | Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. |
| Q37263878 | Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens |
| Q37689799 | Adenovirus-vectored vaccines |
| Q38480709 | Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa |
| Q36446900 | An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses |
| Q64374980 | An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization |
| Q27478104 | An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes |
| Q37945220 | An update on canine adenovirus type 2 and its vectors |
| Q35530297 | Anti-gamma interferon antibodies enhance the immunogenicity of recombinant adenovirus vectors. |
| Q36604795 | Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines |
| Q34447762 | CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination. |
| Q38974187 | Cell-Penetrating Peptides for Antiviral Drug Development |
| Q34657290 | Challenges in the development of an HIV-1 vaccine |
| Q35871539 | Challenges in the search for an HIV vaccine |
| Q39268659 | Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates |
| Q42250611 | Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. |
| Q40345527 | Chimpanzee-origin adenovirus vectors as vaccine carriers. |
| Q36276187 | Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques |
| Q26995655 | Circumventing antivector immunity: potential use of nonhuman adenoviral vectors |
| Q35857420 | Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D |
| Q27481420 | Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses |
| Q38184579 | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines |
| Q34585554 | Current strategies and future directions for eluding adenoviral vector immunity |
| Q35382338 | DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. |
| Q37247948 | Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity |
| Q45488894 | Development of a purification process for adenovirus: controlling virus aggregation to improve the clearance of host cell DNA. |
| Q37713960 | Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model |
| Q36317264 | Development of nonhuman adenoviruses as vaccine vectors |
| Q33558605 | Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization |
| Q37058225 | E. coli Heat-labile Enterotoxin B Subunit as a Platform for the Delivery of HIV Gag p24 Antigen |
| Q33591529 | Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells |
| Q42999099 | Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes |
| Q37137464 | Emerging cancer vaccines: the promise of genetic vectors. |
| Q37567831 | Engineered adenovirus serotypes for overcoming anti-vector immunity |
| Q36629181 | Engineered lentivector targeting of dendritic cells for in vivo immunization |
| Q42255825 | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures |
| Q46773382 | Enhancement of gene transfer to human myeloid cells by adenovirus-fiber complexes |
| Q47911679 | Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys |
| Q43614860 | Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies |
| Q33440600 | Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies |
| Q38400878 | Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial |
| Q40197794 | Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence |
| Q53881163 | From Pasteur to genomics: progress and challenges in infectious diseases. |
| Q37690464 | Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation |
| Q45143982 | HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine |
| Q35227007 | HIV vaccine research: the challenge and the way forward |
| Q36718578 | HIV-1 vaccine development: progress and prospects |
| Q36166161 | HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime |
| Q54217812 | Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. |
| Q37461371 | Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects |
| Q35947690 | Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors |
| Q34204440 | Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors |
| Q45857523 | Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity |
| Q38878799 | Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions |
| Q36498186 | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". |
| Q30369081 | Human infection with highly pathogenic H5N1 influenza virus. |
| Q37123522 | Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors |
| Q43212235 | Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys |
| Q34111806 | Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection |
| Q34075166 | Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection |
| Q53699647 | Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors. |
| Q41752133 | Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice |
| Q33908767 | Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity |
| Q40333540 | Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity |
| Q39612726 | Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys |
| Q36539553 | Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1 |
| Q33234748 | Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers |
| Q34330250 | In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice |
| Q36751598 | Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector |
| Q40474022 | Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. |
| Q40444647 | Interaction of the adenovirus major core protein precursor, pVII, with the viral DNA packaging machinery |
| Q56447686 | International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials |
| Q36409054 | Intranasal delivery of vaccines against HIV. |
| Q34578596 | Issues in the design and implementation of vaccine trials in less developed countries |
| Q43183487 | Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys |
| Q33275292 | Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells |
| Q47207382 | Memory CD8 T-cell compartment grows in size with immunological experience |
| Q34229968 | Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses |
| Q34274849 | New approaches to design HIV-1 T-cell vaccines |
| Q37513550 | New insights on adenovirus as vaccine vectors |
| Q37399747 | Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity |
| Q37743813 | Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques |
| Q36976598 | Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41 |
| Q34257640 | Novel adenovirus vector-based vaccines for HIV-1 |
| Q34541191 | Novel vaccine vectors for HIV-1. |
| Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
| Q42064105 | Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. |
| Q34746476 | Oral adenoviral-based vaccines: historical perspective and future opportunity |
| Q44168559 | Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans |
| Q36427024 | Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. |
| Q36720991 | Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector |
| Q40414104 | Pilot-scale adenovirus seed production through concurrent virus release and concentration by hollow fiber filtration |
| Q37287027 | Post-step modifications for research on HIV vaccines |
| Q34081164 | Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. |
| Q36141586 | Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine |
| Q34045678 | Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity |
| Q30226988 | Production of adenovirus vectors and their use as a delivery system for influenza vaccines |
| Q30342038 | Prospects for an AIDS vaccine: three big questions, no easy answers. |
| Q64378656 | Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes |
| Q24538818 | Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization |
| Q37333924 | Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys |
| Q35949758 | Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon |
| Q36315185 | Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. |
| Q34188729 | Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection |
| Q37082143 | Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2 |
| Q40390251 | Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens |
| Q34477918 | Replication-defective viruses as vaccines and vaccine vectors |
| Q40371848 | Retracing our STEP towards a successful CTL-based HIV-1 vaccine |
| Q38081973 | SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier |
| Q58436528 | Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults |
| Q36158727 | Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study |
| Q37349242 | Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults |
| Q36872938 | Scientific and policy challenges to development of an AIDS vaccine |
| Q37996192 | Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo |
| Q42266669 | Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults |
| Q47282517 | Single-cycle adenovirus vectors in the current vaccine landscape |
| Q35878314 | Structure of human adenovirus |
| Q37365380 | Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys |
| Q41242033 | Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus |
| Q36090185 | T cell vaccines for microbial infections |
| Q36837129 | T-cell immunity generated by recombinant adenovirus vaccines |
| Q34289823 | The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert |
| Q35073652 | The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity |
| Q38088037 | Therapeutic and prophylactic DNA vaccines for HIV-1. |
| Q37270929 | Therapeutic vaccines for non-Hodgkin B-cell lymphoma. |
| Q43244982 | Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination |
| Q41900379 | Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D. |
| Q36751662 | Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model. |
| Q61313589 | Understanding what makes a goodversus a bad vaccine |
| Q34042364 | Use of molecular beacons for rapid, real-time, quantitative monitoring of cytotoxic T-lymphocyte epitope mutations in simian immunodeficiency virus |
| Q36780156 | Use of viral vectors for the development of vaccines |
| Q40400727 | Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency |
| Q33744109 | Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239 |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
| Q42121728 | Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice |
| Q36557330 | Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities |
| Q51204803 | Vaccines: engineering immune evasion. |
| Q33984182 | Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys |
| Q39203396 | What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Rigorous Simian Immunodeficiency Virus Vaccine Trials Can Be Instructive |
| Q30397351 | Yeast Surface-Displayed H5N1 Avian Influenza Vaccines |
Search more.